Pluristem Therapeutics Inc (PSTI)

[HappyBee]

Hi Allo,

Thank you for posting this interesting article and we may be thinking along similar lines.

When you look at the two quotes below, the first from your article and the second from last week's news release, it strikes me that once again it appears that patients in the U.S. fared particularly well. Please correct me, if I'm wrong.

"Whatever this means, it does point to the fact that Europe is very interested in seeing why the initial Phase I trial results for PLX-PAD in CLI were so successful, especially in the U.S. trial."

"Key primary efficacy endpoint, improvement in MWD as compared to placebo, in analysis by country, showed best results with statistically significant improvement (effect size= 51.1%, p=0.015) in U.S patients (n=73) treated with 2 administrations of 300 million PLX-PAD cells."

HappyBee